NCT00874744

Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema

Phase 2 Study of Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Universidade Federal de Goias · Academic / Other
• Sex: All
• Age: 40 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare a single intravitreal injection of 4.0 mg of triamcinolone acetonide and 1.25 mg of bevacizumab for the treatment of diabetic macular edema.

Detailed description

Comparison a single intravitreal injection of 4.0 mg of triamcinolone acetonide and 1.25 mg of bevacizumab regarding the ability of central macular thickness reduction. Secondary objectives are analysis of Visual Outcomes and variations on Intraocular Pressure. The patients data were statistically analyzed if there was a 24 week follow up completed.

Conditions

• Diabetic Macular Edema

Interventions

Type	Name	Description
DRUG	Bevacizumab	1.25mg bevacizumab (0.05ml)
DRUG	Triamcinolone acetonide	4.0 mg Triamcinolone acetonide injection

Timeline

• Start date: 2008-03-01
• Primary completion: 2008-09-01
• Completion: 2008-10-01
• First posted: 2009-04-02
• Last updated: 2009-04-02